Redeye views BeammWave’s rights issue of up to SEK65m as a positive and necessary step to expedite i...
Q2e: Clean paper EBIT of ~PLN 10m Challenging markets Fair value range of SEK 25-70 Q2e Paper EBIT ...
Ahead of Suominen's Q2 report, we maintain our estimates intact.
Redeye comments on last week's news where Google lost its antitrust appeal related to its app store ...
Suominen reports Q2 results on Aug 7. We believe H1’25 earnings will remain rather flat, but H2 shou...
Delays weigh down the quarter’s results.
Solwers’ Board of Directors has today appointed Johan Ehrnrooth as Solwers’ upcoming CEO and he will...
Cancom Q2 PW and cut FY'25 EBITA guidance by -25%, stock -8% Blames reluctant customers, and particu...
Redeye comments on GiG’s preliminary Q2-results which were in line with our forecasts and the announ...
Redeye comments on the partnership with SD Pharma in Spain, which will broaden physician reach of Pe...
Redeye comments on today’s news from Thunderful Group, which includes a SEK50m directed share issue,...
Redeye views the recently announced progress on US reimbursements positively, as a second payor has ...
Adtraction redovisade minskad nettoomsättning och EBITA i det andra kvartalet.
Mendus has fortified its intellectual property (IP) profile for lead candidate, vididencel, with the...
NoHo Partners will publish its Q2 2025 results on 5 August, at around 8:00 EET.
Redeye provides a short comment on the recently announced directed issue from Scandinavian ChemoTech...
Lower sales but demand for shore power solid Cavotec reported sales of EUR 36m (17% below our estima...
Vaisala’s Q2 fell short of our estimates due to weaker than expected performance in W&E.
Physitrack delivered a solid Q2, highlighted by margin expansion, positive free cash flow, and great...
Redeye makes rather small, but positive, changes to our financial forecasts on the back of strong Q2...